Operating Income
Operating Income
Regeneron Pharmaceuticals Operating Income decreased by 26.9% to $642.90M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 8.7%, from $591.70M to $642.90M. Over 4 years (FY 2021 to FY 2025), Operating Income shows a downward trend with a -20.5% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
StatementIncome Statement
SectionOperating Income
CategoryProfitability
SignalHigher is better
VolatilityModerate
First reportedQ1 2013
Last reportedQ1 2026Apr 29, 2026
How to read this metric
Higher operating income indicates strong operational efficiency and pricing power, while a decline suggests rising costs or weakening demand.
Detailed definition
Operating income is the profit realized from a company's core business operations after deducting all operating expenses...
Peer comparison
A standard benchmark for operational performance; peers are compared based on operating margin percentages.
Metric ID:
operating_incomeHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $3.35B | $1.85B | $2.64B | $1.26B | $1.11B | $1.22B | $1.15B | $946.70M | $1.02B | $1.11B | $972.90M | $751.40M | $1.07B | $1.18B | $990.20M | $591.70M | $1.08B | $1.03B | $879.90M | $642.90M |
| QoQ Change | — | -44.8% | +42.9% | -52.3% | -11.8% | +10.3% | -6.3% | -17.4% | +7.4% | +9.3% | -12.4% | -22.8% | +42.3% | +10.3% | -16.0% | -40.2% | +82.4% | -4.9% | -14.3% | -26.9% |
| YoY Change | — | — | — | — | -66.8% | -33.8% | -56.6% | -24.8% | -8.4% | -9.2% | -15.2% | -20.6% | +5.2% | +6.2% | +1.8% | -21.3% | +0.9% | -12.9% | -11.1% | +8.7% |
Range$591.70M – $3.35B
CAGR-29.3%
Avg YoY Growth-16.1%
Median YoY Growth-12.0%
Current Streak3 quarters decline
Operating Income at Other Companies
Frequently Asked Questions
- What is Regeneron Pharmaceuticals's operating income?
- Regeneron Pharmaceuticals (REGN) reported operating income of $642.90M in Q1 2026.
- How has Regeneron Pharmaceuticals's operating income changed year-over-year?
- Regeneron Pharmaceuticals's operating income increased by 8.7% year-over-year, from $591.70M to $642.90M.
- What is the long-term trend for Regeneron Pharmaceuticals's operating income?
- Over 4 years (2021 to 2025), Regeneron Pharmaceuticals's operating income has grown at a -20.5% compound annual growth rate (CAGR), from $8.95B to $3.58B.
- What does operating income mean?
- The profit a company makes from its core business operations before interest and taxes.